de Jong DLK, et al. - Among patients with mild-to-moderate Alzheimer disease, the impact of 6 months of treatment with the calcium antagonist nilvadipine on cerebral blood flow (CBF) was evaluated in this randomized, double-blind, placebo-controlled study. Out of 58 patients, 22 had no magnetic resonance exclusion criteria and were medication compliant over 6 months. The participants had a mean age of 72.8±6.2 years and mean mini-mental state examination was 20.4±3.4. Attenuated blood pressure and increased CBF in the hippocampus were the consequences of nilvadipine treatment. Stable or small nonsignificant increases in CBF were seen in other regions. Preserved cerebral autoregulation in Alzheimer disease was suggested by the results of antihypertensive treatment, along with beneficial cerebrovascular effects.